Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals announced its second quarter 2026 financial results, highlighting significant clinical progress in its EP-104GI trial for eosinophilic esophagitis (EoE), including improvements in fibrosis and inflammation. The company has strengthened its executive team and board to support late-stage development and commercialization effo…